Double attack on tumors: freeze then irradiate shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged ≥18 years; * Histologically or cytologically confirmed solid tumor that is unresectable and for which local therapy is clinically appropriate; * At least one prespecified target lesion suitable for percutaneous image-guided treatment and considered technically feasible for both 125I seed implantation and cryoablation per investigator assessment (and protocol-defined anatomic/dosimetric safety criteria); * ECOG performance status 0-2; * Adequate organ function, acceptable coagulation status, and the ability to safely undergo percutaneous image-guided procedures; * Written informed consent provided. Exclusion Criteria: * Prior 125I seed implantation or cryoablation to the same target lesion(s), or other local therapy to the target lesion(s); * Target lesion location or anatomy that, in the investigator's judgment, makes either procedure unsafe or unlikely to achieve protocol-defined coverage/ablation (e.g., inability to meet organ-at-risk constraints or required safety margins); * Uncontrolled bleeding risk or coagulopathy not correctable per protocol; inability to safely hold/bridge anticoagulants/antiplatelets as required. Active, uncontrolled infection, including uncontrolled local infection at the intended procedure site; * Clinically significant uncontrolled comorbidities that increase procedural risk; * Severe organ dysfunction that precludes procedures or follow-up, per protocol-defined thresholds.; * Pregnancy or breastfeeding; * Known hypersensitivity to materials/medications essential for the procedures (e.g., contrast agents or anesthetics) that cannot be adequately managed; * Any condition that would impair reliable outcome assessment or adherence (e.g., inability to undergo required imaging, expected poor compliance), per investigator judgment.